menu
    • menu
    [{"orgOrder":0,"company":"Maruho","sponsor":"BiomX","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"BX005","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Maruho \/ Maruho Co. Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"Maruho \/ Maruho Co. Ltd."},{"orgOrder":0,"company":"Maruho","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Maruho","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Wipes","sponsorNew":"Maruho \/ Maruho Co","highestDevelopmentStatusID":"12","companyTruncated":"Maruho \/ Maruho Co"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"12","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"BiomX","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BX005","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"EVO756","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Maruho","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"AOBiome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"B244","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Maruho \/ Chugai Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Maruho

    Menu

    Maruho

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Maruho Launches Mitchga SC Injection for Pruritus in Japan

                            Details : Mitchga (nemolizumab) is an anti-IL-31 receptor A humanized monoclonal antibody, which is approved for the treatment of atopic dermatitis and prurigo nodularis.

                            Brand Name : Mitchga

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 12, 2024

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis

                            Details : Mitchga (nemolizumab) is an anti-IL-31 receptor A humanized monoclonal antibody, which is approved for the treatment of atopic dermatitis and prurigo nodularis.

                            Brand Name : Mitchga

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 26, 2024

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : AOBiome Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AOB Pharma Enters License Agreement for Topical Biologic B244 in Japan

                            Details : The agreement aims to develop AOB's topical biologic B244, preparing for global Phase 3 trials, a therapeutic for dermatological conditions like Atopic Dermatitis and pruritus.

                            Brand Name : B244

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 05, 2024

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : AOBiome Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Evommune

                            Deal Size : $60.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 Antagonist EVO756 ...

                            Details : The collaboration aims to develop and commercialize EVO756 in Japan. Evommune’s MRGPRX2 antagonist, is an investigational therapy with the potential to be a first-in-class oral treatment for a variety of mast cell mediated disease.

                            Brand Name : EVO756

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 27, 2023

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Evommune

                            Deal Size : $60.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoclonal Antibody Mitchga for the Treatment of ...

                            Details : Mitchga (Nemolizumab) is the first antibody drug targeting IL-31 receptor A, for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective).

                            Brand Name : Mitchga

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 08, 2022

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BX005

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Recipient : BiomX

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IND Accepted to Conduct Clinical Testing of BX005 for the Treatment of Atopic Dermatitis

                            Details : BX005 is currently in the final stages of GMP production. The Company continues to expect the first data readout from its Phase 1/2 proof-of-concept trial evaluating the safety and efficacy.

                            Brand Name : BX005

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 11, 2022

                            Lead Product(s) : BX005

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : BiomX

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxolitinib Phosphate

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Incyte Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan

                            Details : Maruho will receive the rights to develop, manufacture and exclusively commercialize ruxolitinib cream, and other potential future topical formulations of ruxolitinib, in autoimmune and inflammatory dermatologic diseases, including vitiligo and atopic de...

                            Brand Name : Opzelura

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 28, 2022

                            Lead Product(s) : Ruxolitinib Phosphate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Incyte Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Maruho Obtained Regulatory Approval for Mitchga, the First Antibody Targeting IL-31 for Itching Associated wit...

                            Details : The approval of Mitchga, the first antibody-drug targeting interleukin-31, is based on the results from a Japanese phase III clinical study in patients with moderate to severe AD who are older than 13 years old and are tolerant to existing treatments.

                            Brand Name : Mitchga

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 28, 2022

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Chugai Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycopyrronium Tosylate

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Journey Medical Corporation

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Milli...

                            Details : QBREXZA (Rapifort® Wipes 2.5%), is a topical product approved by the U.S. Food and Drug Administration for treatment of primary axillary hyperhidrosis in adult and pediatric populations (ages nine-years and older) and is self-administered by patients.

                            Brand Name : Rapifort Wipes

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 11, 2022

                            Lead Product(s) : Glycopyrronium Tosylate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Journey Medical Corporation

                            Deal Size : $10.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed

                            Maruho

                            Japan arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BX005

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Recipient : BiomX

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

                            Details : Maruho also entered into a binding agreement for an equity investment in BiomX of $3 million at a premium to the market share price, intended primarily to support the Phase 1/2 study of atopic dermatitis product candidate, BX005, in Japan.

                            Brand Name : BX005

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 13, 2021

                            Lead Product(s) : BX005

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Recipient : BiomX

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth